Active, not recruitingPhase 2NCT03767348
Study of RP1 Monotherapy and RP1 in Combination With Nivolumab (IGNYTE)
Studying Small cell lung cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Replimune Inc.
- Principal Investigator
- Jeannie Hou, MDReplimune Inc.
- Intervention
- RP1(biological)
- Enrollment
- 340 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2028
Study locations (30)
- University of Birmingham Alabama, Birmingham, Alabama, United States
- Banner MD Anderson Cancer Center, Gilbert, Arizona, United States
- Mayo Clinic, Phoenix, Arizona, United States
- Carti Cancer Center, Little Rock, Arkansas, United States
- UC San Diego, La Jolla, California, United States
- University of Southern California, Los Angeles, California, United States
- UCLA, Los Angeles, California, United States
- University of California, Irvine, Orange, California, United States
- University of California- San Francisco, San Francisco, California, United States
- Sylvester Comprehensive Cancer Center- University of Miami, Miami, Florida, United States
- University of Iowa-Cancer Center Research, Iowa City, Iowa, United States
- James Graham Brown Cancer Center- University of Louisville, Louisville, Kentucky, United States
- Mayo Clinic, Rochester, Minnesota, United States
- New York University Clinical Cancer Center, New York, New York, United States
- Weill Cornell Medical College, New York, New York, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
Bristol-Myers Squibb
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03767348 on ClinicalTrials.govOther trials for Small cell lung cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT06694454Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)National Cancer Institute (NCI)
- RECRUITINGNANCT07398599Double-Dose Third-Generation EGFR-TKI Plus Bevacizumab and Intrathecal Chemotherapy for Refractory Leptomeningeal Metastatic NSCLC: A Phase II StudySecond Affiliated Hospital of Nanchang University
- RECRUITINGPHASE1, PHASE2NCT07480213Adaptive Phase 1/2 Study of Dual-Target CAR-NK Cells in Relapsed/Refractory Small Cell Lung Cancer (SCLC)Beijing Biotech
- RECRUITINGPHASE2NCT07329322Phase II Study of Sacituzumab Tirumotecan in Combination With Osimertinib or Sacituzumab Tirumotecan for Neoadjuvant Treatment in Patients With Resectable Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung CancerSichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
- RECRUITINGPHASE1, PHASE2NCT07227597A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003)Merck Sharp & Dohme LLC
- RECRUITINGPHASE1NCT07348211First in Human Study of SIM0610 in Solid TumorsJiangsu Simcere Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07161310Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint InhibitorsGoethe University
- RECRUITINGPHASE2NCT07304739Furmonertinib Combined With Intrathecal Chemotherapy and Stereotactic Radiotherapy (SRT) for EGFR-Mutated NSCLC Patients With Brain Parenchymal and Leptomeningeal MetastasesTianjin Medical University Cancer Institute and Hospital